Breast cancer is one of the most common malignant tumors in women, and its incidence rate is increasing year by year. The incidence rate of breast cancer has risen to the first place among female malignant tumors in many major cities in China, becoming the biggest threat to women’s health. Although the above treatments have achieved some success, almost all advanced breast cancers and many early breast cancers eventually fail to be treated. The special structure and mechanism of action of conventional chemotherapeutic agents determine their poor selectivity and resistance to drugs in breast cancer cells. Therefore, the development of anti-breast cancer drugs with high selectivity and sensitivity is the urgent need to improve the level of comprehensive breast cancer treatment. The emergence of molecular targeted therapy has brought new hope to breast cancer patients. Molecular targeted therapies are aimed at targets that may lead to cellular carcinogenesis, such as proto-oncogenes and oncogenes, cell signaling pathways, cytokines and receptors, and anti-tumor angiogenesis, to reverse the malignant biological behavior at the molecular level and thus inhibit the growth of tumor cells. Molecular targeted therapy for breast cancer is another effective clinical treatment after chemotherapy and endocrine therapy.